Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Erika Cavallone"'
Autor:
Weiyun Z. Ai, Jonathan E. Brammer, Pierluigi Porcu, Frank McCormick, Lawrence K. Kaplan, Charalambos Andreadis, Basem M. William, Matthew J. Wieduwilt, Laura Pincus, Pamela Heeter, Wade Berry, Erika Cavallone, Aaron Zhan, Chen-Yen Yang, Chi-Heng Wu, Khoan Vu
Table S1, S2, S3, S4 Fig. S1, S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5147379e8f8e968eeeb49d8e38d67438
https://doi.org/10.1158/1078-0432.22476672
https://doi.org/10.1158/1078-0432.22476672
Autor:
Weiyun Z. Ai, Jonathan E. Brammer, Pierluigi Porcu, Frank McCormick, Lawrence K. Kaplan, Charalambos Andreadis, Basem M. William, Matthew J. Wieduwilt, Laura Pincus, Pamela Heeter, Wade Berry, Erika Cavallone, Aaron Zhan, Chen-Yen Yang, Chi-Heng Wu, Khoan Vu
Purpose:The histone deacetylase (HDAC) inhibitor romidepsin and the anthracycline liposomal doxorubicin (LD) have modest single-agent activity in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). We investigated the safety and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e434c4487d5c150e5875623644f8fb
https://doi.org/10.1158/1078-0432.c.6529458.v1
https://doi.org/10.1158/1078-0432.c.6529458.v1
Autor:
Pamela Heeter, Erika Cavallone, Frank McCormick, Lawrence K. Kaplan, Laura B. Pincus, Wade Berry, Basem M. William, Aaron Zhan, Khoan Vu, Jonathan E. Brammer, Chen-Yen Yang, Charalambos Andreadis, Matthew J. Wieduwilt, Pierluigi Porcu, Weiyun Z. Ai, Chi-Heng Wu
Publikováno v:
Clinical Cancer Research. 26:1000-1008
Purpose: The histone deacetylase (HDAC) inhibitor romidepsin and the anthracycline liposomal doxorubicin (LD) have modest single-agent activity in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). We investigated the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3bb55df541f8f4ab426bc850b557abc
https://doi.org/10.1158/1078-0432.ccr-19-2152
https://doi.org/10.1158/1078-0432.ccr-19-2152
Autor:
Diem Le, Teresa Ta, Erika Cavallone, Joseph Tuscano, Swetha Kambhampati, Charalambos Andreadis, Matthew J. Wieduwilt, Michelle Padilla, Weiyun Z. Ai, Jesika Reiner, Miguel Castillo, Erika Crawford, Lawrence D. Kaplan, Bita Fakhri, Akshay Sudhindra, Michelle Martinelli, Charlie Aoun
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(3)
Introduction We designed a multicenter, phase Ib dose-escalation trial of carfilzomib with bendamustine and rituximab in patients with relapsed/refractory non-Hodgkin lymphoma ( NCT02187133 ) in order to improve the response rates of this difficult-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230b02c8d73a5c8b17d734849db3722e
https://pubmed.ncbi.nlm.nih.gov/33478921
https://pubmed.ncbi.nlm.nih.gov/33478921